AstraZeneca announced a research collaboration with Shenzhen University Health Science Center.
The partners will undertake pre-clinical research focused on chronic kidney disease (CKD), which represents a large and growing unmet medical need in China.
Scientists from Shenzhen University Health Science Center’s Nephrology and Urology Center will work in collaboration with teams from AstraZeneca’s Innovation Center China in Shanghai, bringing together complementary skills that will harness and foster medical innovation.
Financial details of the agreement were not disclosed.
As a priority, the partners will focus on diabetic nephropathy, damage to the kidneys caused by diabetes, which, in severe cases, can lead to kidney failure.
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with AstraZeneca
Report: Alzheimer’s Disease Partnering
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity